- Up to $15 million available in three $5 million tranches; additional $25 million potentially available - VANCOUVER, Aug. 22, 2018 /CNW/ - Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage...
- More than 1,200 patients treated to date with momelotinib, including in two Phase 3 trials; ongoing therapy for more than seven years in some patients - - Demonstrated meaningful anemia-related...
- SRA737 Monotherapy trial prioritized for ovarian cancer; targeting enrollment of 65 patients with preliminary data anticipated in H1 2019 - - SRA737 LDG Combination trial to be amended and...
View all news releases
Analyst & Investor Call to Discuss Sierra’s Acquisition of Momelotinib from Gilead
View All Presentations
Members of the professional investment community may participate by phone by calling: Toll-free in North America: (866) 548-4713 International Dial-in: (323) 794-2093 Conference ID: 6356543
View all events and webcasts
James Smith, Vice President Corporate Affairs
Sign up for investor alerts